Merus N.V. Announces Proposed Public Offering of Common Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Merus N.V. (MRUS) PT Raised to $85 at H.C. Wainwright
May 29, 2024 6:20 AM EDTH.C. Wainwright analyst Andrew Fein raised the price target on Merus N.V. (NASDAQ: MRUS) to $85.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "Valuation and risks to reaching our price target. Given the recent ASCO update for petosemtamab, we are... More
Merus N.V. (MRUS) PT Raised to $80 at BofA Securities
May 29, 2024 5:13 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Merus N.V. (NASDAQ: MRUS) to $80.00 (from $61.00) while maintaining a Buy rating.
The analyst comments "Merus reported 67% objective response rate (ORR; 1 CR, 15 PR) in 24 evaluable 1L head and neck squamous cell carcinoma (HNSCC)... More
